Saltar al contenido principal
Elsevier

Metabolic Steatotic Liver Disease

Current Knowledge, Therapeutic Treatments, and Future Directions

  • 1 Edición - 21 de junio de 2024
  • Última edición
  • Editores: Mindie Nguyen, Linda Henry
  • Idioma: Inglés

Metabolic Fatty Liver Disease: Current Knowledge, Therapeutic Treatments, and Future Directions provides the most updated research findings and defines the current data gaps on m… Leer más

Descripción

Metabolic Fatty Liver Disease: Current Knowledge, Therapeutic Treatments, and Future Directions provides the most updated research findings and defines the current data gaps on metabolic fatty liver disease. The book extensively covers key areas in metabolic fatty liver disease research, including epidemiology (adults and children), economic burden, patient-reported outcome burden, natural history, current treatments, current diagnostic methods, controversies (NAFLD/MAFLD), current guidelines, fatty liver disease in the presence of other liver diseases as well as guidance on future research.

This book will provide translational researchers with a current and comprehensive resource dedicated to all aspects of research in metabolic fatty liver disease, identify current gaps in research and make future research recommendations. It also offers clinicians a look at important background information in metabolic fatty liver disease and thoroughly reviews the latest research in this area to inform treatment outcomes.

Puntos claves

  • Compiles the latest, up-to-date science from key experts in the field on metabolic fatty liver disease
  • Reviews best practices and current guidelines for a comprehensive overview
  • Identifies recommendations for future research endeavors

De interès para

Translational and clinical science researchers in digestive medicine; gastroenterologists and hepatologists, Bariatric surgeons, transplant surgeons, nutritionists, endocrinologists, cardiologists, public and health policy makers

Índice

1. Global Epidemiology of NAFLD (now and forecasted)

2. U.S. Epidemiology of NAFLD (now and forecasted). Linda Henry, PhD; Stanford University, USA

3. Economic and patient reported outcome burden (now and forecasted)

4. NAFLD pathogenesis (environmental and genetic)

5. Clinical presentation and natural history.6. Non-liver comorbidities (prevalence and incidence)

7. Screening, diagnosis, and evaluation of patients with NALFD

8. Non-invasive evaluation of liver fibrosis (serum-based)

9. Non-invasive evaluation of liver fibrosis (imaging/elastography-based)

10. General treatment principles

11. Non-surgical treatment of obesity and metabolic disease

12. Endoscopic and surgical treatment of obesity

13. Pharmacologic treatment of hepatic steatosis

14. Overview and comparison of current guidelines (AASLD, EASL, APASL) on NAFLD and MAFLD controversies

15. Special populations: Fatty liver disease in children and adolescent and in the presence of other liver diseases

16. Special populations: Fatty liver disease in patients with chronic hepatitis

Detalles del producto

  • Edición: 1
  • Última edición
  • Publicado: 25 de junio de 2024
  • Idioma: Inglés

Sobre los editores

MN

Mindie Nguyen

Dr. Nguyen is Professor of Medicine and Director for the Hepatology Fellowship in the Division of Gastroenterology and Hepatology and Liver Transplant Program and by courtesy Professor of Epidemiology and Population Health at Stanford University Medical Center and Director for the Hepatology Clerkship for Stanford University School of Medicine. She is also a member of the Stanford Cancer Institute, Stanford Bio-X and Stanford Population Science. She has served as a member of the Appointment and Promotion Committee for the Department of Medicine as well as a Diversity LENS Advocate for the Department. She is both clinically active and does research with single-center Stanford-based cohorts, multi-center Bay Area consortium, multi-center US consortia as well as international cohorts. She is a Fellow of the American Association for the Study of Liver Diseases and the American Gastroenterological Association, as well as member of the American College of Gastroenterology, European Association for the Study of Liver Diseases and the Asia Pacific Association for the Study of Liver Diseases.
Afiliaciones y experiencia
Professor of Medicine and Director, Hepatology Fellowship, Division of Gastroenterology and Hepatology and Liver Transplant Program; Courtesy Professor of Epidemiology and Population Health, Stanford University Medical Center; Director, Hepatology Clerkship for Stanford University School of Medicine

LH

Linda Henry

Linda Henry is an academic researcher from Stanford University. The author has contributed to research in topic(s): Hepatitis C & Sofosbuvir. The author has an hindex of 42, co-authored 197 publication(s) receiving 12359 citation(s). Previous affiliations of Linda Henry include Inova Health System & University of Florida.
Afiliaciones y experiencia
Academic Researcher, Stanford University, USA

Ver libro en ScienceDirect

Lee Metabolic Steatotic Liver Disease en ScienceDirect